Project description
New platform for early diagnosis of Alzheimer’s disease
The estimation of functional decline in early Alzheimer’s disease (AD) is crucial for the treatment of patients. The EU-funded RADAR-AD project will develop a digital platform to discover minuscule functional deficits in early AD patients. The platform will integrate a combination of smartphone, wearable and home sensor-based parameters adequate for longitudinal studies and tests, identify the most relevant functional domains and the most encouraging remote measurement tools (RMTs). It will test the platform and selected RMTs in a real-world environment consisting of 240 participants, and perform statistical modelling to assess longitudinal predictions. RADAR-AD will discuss the results with regulatory agencies, patients and carer groups to acquire knowledge and guidance for future treatments.
Objective
There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful combination of smartphone, wearable and/or home sensor based parameters. The system developed will be suitable for future longitudinal studies, including trials. The objectives are to 1) Identify the most relevant functional domains and the most promising remote measurement tools (RMTs) for these domains based on reviewing the literature and piloting of RMTs in small studies; 2) Optimise the RADAR-CNS platform for use in AD studies; 3) Test the platform and selected RMTs in a real world environment clinical study with 240 participants across the AD spectrum ranging from the preclinical AD to the dementia stage; 4) Perform statistical modelling to estimate longitudinal predictions; 5) Discuss results with regulatory agencies in order to obtain guidance about how to develop a path for formal qualification as outcome measurements in future therapeutic interventions. Considering the limited budget and project duration, we will rely upon already available technology platforms and on available longitudinal datasets where possible. The consortium includes experts in clinical dementia studies, computer science, bioinformatics, regulatory policies, ethics, and patient and public involvement (PPI). Additional strengths of the consortium are the deep and broad interface with RADAR-CNS and related IMI projects, and the access to large amount of patient-level data from key European cohort studies for modelling purposes.
Fields of science
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- natural sciencescomputer and information sciences
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
WC2R 2LS London
United Kingdom
See on map
Participants (16)
3521 AL Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1081 HV Amsterdam
See on map
3511 MJ Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
OX1 2JD Oxford
See on map
17177 Stockholm
See on map
3531AH Utrecht
See on map
80686 Munchen
See on map
1736 SENNINGERBERG
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2340 Beerse
See on map
Participation ended
WC2B 4AE London
See on map
4056 Basel
See on map
RG21 4FA Basingstoke
See on map
64297 Darmstadt
See on map
57001 Thermi Thessaloniki
See on map
6003 Luzern
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
8152 Glattpark
See on map